WO2014027777A3 - 신규한 우르솔릭산 유도체 및 이의 제조 방법 - Google Patents

신규한 우르솔릭산 유도체 및 이의 제조 방법 Download PDF

Info

Publication number
WO2014027777A3
WO2014027777A3 PCT/KR2013/007003 KR2013007003W WO2014027777A3 WO 2014027777 A3 WO2014027777 A3 WO 2014027777A3 KR 2013007003 W KR2013007003 W KR 2013007003W WO 2014027777 A3 WO2014027777 A3 WO 2014027777A3
Authority
WO
WIPO (PCT)
Prior art keywords
ursolic acid
acid derivative
preparing same
novel
prodrug
Prior art date
Application number
PCT/KR2013/007003
Other languages
English (en)
French (fr)
Other versions
WO2014027777A2 (ko
Inventor
윤여홍
권돈선
Original Assignee
한국콜마 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국콜마 주식회사 filed Critical 한국콜마 주식회사
Priority to US14/420,978 priority Critical patent/US9120839B2/en
Priority to CN201380051469.1A priority patent/CN104684883A/zh
Publication of WO2014027777A2 publication Critical patent/WO2014027777A2/ko
Publication of WO2014027777A3 publication Critical patent/WO2014027777A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J75/00—Processes for the preparation of steroids in general

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

본 발명은 우수한 안정성 및 경구 흡수도 등 약동력학적 특성을 가질 수 있는 우르솔릭산의 전구 약물 형태로서, 체내에서 우르솔릭산으로 전환되어 우수한 약학적 활성을 나타낼 수 있는 우르솔릭산 전구 약물 형태의 신규한 우르솔릭산 유도체 및 이의 제조 방법에 관한 것이다. 상기 우르솔릭산 유도체는 우르솔릭산의 C28의 카르복실산에 소정 약학적 화합물의 전구 약물이 결합된 에스테르 형태를 가질 수 있다.
PCT/KR2013/007003 2012-08-14 2013-08-02 신규한 우르솔릭산 유도체 및 이의 제조 방법 WO2014027777A2 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US14/420,978 US9120839B2 (en) 2012-08-14 2013-08-02 Ursolic acid derivative and method for preparing same
CN201380051469.1A CN104684883A (zh) 2012-08-14 2013-08-02 新型乌索酸衍生物及其制备方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2012-0089026 2012-08-14
KR20120089026 2012-08-14
KR10-2013-0091893 2013-08-02
KR1020130091893A KR101889528B1 (ko) 2012-08-14 2013-08-02 신규한 우르솔릭산 유도체 및 이의 제조 방법

Publications (2)

Publication Number Publication Date
WO2014027777A2 WO2014027777A2 (ko) 2014-02-20
WO2014027777A3 true WO2014027777A3 (ko) 2014-04-10

Family

ID=50269291

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2013/007003 WO2014027777A2 (ko) 2012-08-14 2013-08-02 신규한 우르솔릭산 유도체 및 이의 제조 방법

Country Status (4)

Country Link
US (1) US9120839B2 (ko)
KR (1) KR101889528B1 (ko)
CN (1) CN104684883A (ko)
WO (1) WO2014027777A2 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106138063A (zh) * 2015-04-23 2016-11-23 苏州大学附属第医院 熊果酸的用途

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202090438A1 (ru) 2017-08-04 2020-06-15 Арделикс, Инк. Производные глицерретиновой кислоты для лечения гиперкалиемии
KR20200083969A (ko) 2017-09-14 2020-07-09 피닉스 바이오테크놀러지 인코포레이티드. 신경학적 상태를 치료하기 위한 방법 및 개선된 신경보호 조성물
AU2018334386B2 (en) 2017-09-14 2021-11-04 Phoenix Biotechnology, Inc. Method and composition for treating viral infection
KR102130572B1 (ko) * 2018-07-11 2020-07-06 차의과학대학교 산학협력단 극난용성이 개선 된 신규한 우르솔릭산 공결정 또는 복합제
MX2021009491A (es) * 2019-02-07 2021-09-08 Ardelyx Inc Compuestos y metodos para tratar la hiperpotasemia.
SG11202105728YA (en) 2020-03-31 2021-11-29 Phoenix Biotechnology Inc Method and compositions for treating coronavirus infection
EP4009981B1 (en) 2020-03-31 2023-08-16 Phoenix Biotechnology, Inc. Method and compositions for treating coronavirus infection
KR20240077665A (ko) * 2022-11-24 2024-06-03 국립암센터 Prd-2001을 포함하는 암 예방 또는 치료용 약학적 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101792477A (zh) * 2010-03-02 2010-08-04 福州大学 具抗癌活性的乙酰熊果酰三乙醇胺单酯及其制备方法
CN101928322A (zh) * 2010-03-02 2010-12-29 福州大学 具抗癌活性的熊果酸修饰物多元醇单酯
US20110190388A1 (en) * 2010-02-02 2011-08-04 Kaohsiung Medical University Ursolic acid derivative and pharmaceutical composition thereof
CN102558279A (zh) * 2011-11-09 2012-07-11 四川国康药业有限公司 熊果酸-3’-取代丙醇酯衍生物的合成及抗肿瘤活性研究

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3909089A (en) 1974-07-08 1975-09-30 Plastics Inc Container for storing and carrying articles
IT1215626B (it) 1982-07-26 1990-02-22 Isf Spa Derivato dell'acido ursolico farmacologicamente attivo.
CA2611435C (en) 2005-06-10 2013-01-08 Pola Chemical Industries Inc. Novel triterpenic acid derivative and preparation for external application for skin comprising the same
JP5402349B2 (ja) 2009-07-23 2014-01-29 ソニー株式会社 固体撮像装置とその駆動方法、及び電子機器

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110190388A1 (en) * 2010-02-02 2011-08-04 Kaohsiung Medical University Ursolic acid derivative and pharmaceutical composition thereof
CN101792477A (zh) * 2010-03-02 2010-08-04 福州大学 具抗癌活性的乙酰熊果酰三乙醇胺单酯及其制备方法
CN101928322A (zh) * 2010-03-02 2010-12-29 福州大学 具抗癌活性的熊果酸修饰物多元醇单酯
CN102558279A (zh) * 2011-11-09 2012-07-11 四川国康药业有限公司 熊果酸-3’-取代丙醇酯衍生物的合成及抗肿瘤活性研究

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KALANI, K . ET AL.: "Pharmacophore, QSAR, and ADME based semisynthesis and in vitro evaluation of ursolic acid analogs for anticancer activity", JOURNAL OF MOLECULAR MODELING, vol. 18, 21 January 2012 (2012-01-21), pages 3389 - 3413, XP035075607, DOI: doi:10.1007/s00894-011-1327-6 *
ZHONG, Y. ET AL.: "Synthesis, stability and pharmacological evaluation of a novel codrug consisting of lamivudine and ursolic acid", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 45, 9 November 2011 (2011-11-09), pages 110 - 115, XP028341135, DOI: doi:10.1016/j.ejps.2011.10.028 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106138063A (zh) * 2015-04-23 2016-11-23 苏州大学附属第医院 熊果酸的用途

Also Published As

Publication number Publication date
US9120839B2 (en) 2015-09-01
KR101889528B1 (ko) 2018-08-17
CN104684883A (zh) 2015-06-03
US20150218206A1 (en) 2015-08-06
KR20140024215A (ko) 2014-02-28
WO2014027777A2 (ko) 2014-02-20

Similar Documents

Publication Publication Date Title
WO2014027777A3 (ko) 신규한 우르솔릭산 유도체 및 이의 제조 방법
IL254839B (en) Derivatives of piperidine-4- and -2-carboxylic acids, perhydroazepine-4-carboxylic acid and (piperidin-4-yl)-acetic acid and pharmaceutical compositions comprising them
WO2014004902A3 (en) Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof
PT3412676T (pt) Derivados cíclicos de éster de ácido borónico, método para a sua preparação e suas utilizações terapêuticas
WO2014014835A8 (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
WO2013024114A3 (de) Biotechnologisches syntheseverfahren von omega-funktionalisierten carbonsäuren und carbonsäure-estern aus einfachen kohlenstoffquellen
PL2678322T3 (pl) Estry pentylu kwasu furanodikarboksylowego jako plastyfikatory
WO2011012816A3 (fr) Formulation pharmaceutique
LT2785205T (lt) Priešmikrobinis aldehidų, organinių rūgščių ir organinių rūgščių esterių mišinys
NZ729443A (en) Heterocyclic modulators of lipid synthesis
EP2611764A4 (en) FERMENTATION ROUTE FOR THE PRODUCTION OF LÉVULINIC ACID, LEVULINATE ESTERS, VALÉROLACTONE, AND CERTAIN OF THEIR DERIVATIVES
PL2870134T3 (pl) Zastosowanie estrów kwasów karboksylowych jako smarów
WO2011146583A3 (en) Nanoparticulate cinacalcet formulations
HK1206358A1 (en) Process for the preparation of pyrazole carboxylic acid derivatives
EP2560633B8 (en) Intravenous omega-3 fatty acid compositions & method of use
ZA201303357B (en) Ketocarboxylic acids, ketocarboxylic esters, methods of manufacture and uses thereof
WO2011015287A3 (en) Process for the preparation of derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid
WO2011142731A3 (en) Formulations comprising a third generation cephalosporin and clavulanic acid
SI2614057T1 (sl) Soli estrov 7-amino-3,5-dihidroksi heptanojske kisline
MY164880A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids
WO2011136513A3 (ko) 디히드록시벤조산 유도체를 포함하는 골이식용 또는 골충진용 조성물
MX2013012773A (es) Sustancias farmacologicas, composiciones farmaceuticas y metodos para la preparacion de las mismas.
MX2013002694A (es) Derivados de tetrahidroquinolina usados como activadores de proteina cinasa activada por monofosfato de adenosina.
EP2639218A4 (en) NEW CARBOXYLIC ACID ESTER COMPOUND, ITS PREPARATION AND PARFUM COMPOSITION THEREWITH
IN2014DN07407A (ko)

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 14420978

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13879585

Country of ref document: EP

Kind code of ref document: A2